Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Positive safety data from phase I/II study of HuMax-EGFr

Oct. 6, 2004

European submission seeks approval of Dacogen for MDS

Oct. 6, 2004

Analogues of antiangiogenic agent NM-3 show enhanced antiproliferative activity in vivo

Oct. 6, 2004

Combination treatment with Abbott PARP inhibitor and doxorubicin increases life span

Oct. 6, 2004

Selective topoisomerase I poison for cancer therapy

Oct. 6, 2004

A PABA combination regimen shows promise in refractory melanoma

Oct. 5, 2004

RTA-203: a new mammalian V-ATPase inhibitor in preclinical testing

Oct. 5, 2004

Tarceva NDA accepted for priority review

Oct. 5, 2004

AP-23573 enters phase II study for bone and soft tissue sarcomas

Oct. 5, 2004

Multiple targets elucidated for anti-GI cancer agent HKH-40A

Oct. 5, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.